The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell lung cancer

摘要: Abstract Objectives In non-small cell lung cancer (NSCLC), the association between common EGFR mutations (Del EX19/L858R) with tyrosine kinase inhibitors (EGFR-TKIs) has been well established. However, this not investigated for rare or their impact on treatment response and outcome to TKIs (primary objective) chemotherapy (secondary objective). Materials methods an observational prospective cohort, we analyzed 188 NSCLC patients from Mexico, Colombia Costa Rica mutations. As a first line of treatment, 66.5% received platinum-based chemotherapy. All in first-line after progression The clinical–pathological characteristics as f associated were analyzed. Results Of all patients, 79.5% had 20.5% Lepidic acinar adenocarcinomas ( p =0.010). Patients higher rates EGFR-TKIs than those who (63.8 vs 32.4%, =0.02). median PFS overall survival (OS) better (15.5 3.9 months, Conclusion Our findings suggested that only could receive due low short EGFR-TKIs. Consequently, be reserved second- third-line treatment. mutations, women have men, are more frequent high grade tumors.